BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15386352)

  • 1. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
    Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
    Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer.
    Hazelbag S; Gorter A; Kenter GG; van den Broek L; Fleuren G
    Hum Pathol; 2002 Dec; 33(12):1193-9. PubMed ID: 12514788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.
    Hazelbag S; Kenter GG; Gorter A; Dreef EJ; Koopman LA; Violette SM; Weinreb PH; Fleuren GJ
    J Pathol; 2007 Jul; 212(3):316-24. PubMed ID: 17503414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
    Kobayashi H; Fujishiro S; Terao T
    Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lgr5 is a potential prognostic marker in patients with cervical carcinoma.
    Sun B; Ye X; Li Y; Zhang W
    Int J Clin Exp Pathol; 2015; 8(2):1783-9. PubMed ID: 25973068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
    Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
    Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
    Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
    Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.
    Xu C; Wang Z; Cui R; He H; Lin X; Sheng Y; Zhang H
    BMC Cancer; 2015 Nov; 15():925. PubMed ID: 26597083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
    Horn LC; Pippig S; Raptis G; Fischer U; Köhler U; Hentschel B; Martin R
    Aust N Z J Obstet Gynaecol; 2002 Oct; 42(4):383-6. PubMed ID: 12403286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stomatin-like protein 2 expression is associated with clinical survival in patients with cervical cancer.
    Xiao B; Xie Z; Guo L; Wu J; Zhang H
    Int J Clin Exp Pathol; 2015; 8(2):1804-9. PubMed ID: 25973071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene.
    Hageman J; Eggen BJ; Rozema T; Damman K; Kampinga HH; Coppes RP
    Clin Cancer Res; 2005 Aug; 11(16):5956-64. PubMed ID: 16115939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.